Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study

Abstract

S. boulardii improved anti-H. pylori antibiotherapy-associated diarrhea, epigastric discomfort, and treatment tolerability. In addition, S. boulardii supplement decreased post-treatment dyspepsia symptoms independent of H. pylori status. However, S. boulardii had no significant affect on the rate of H. pylori eradication.

Intervention study on Saccharomyces boulardii with proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori related peptic ulcer

“…Moreover, the side effects were significantly decreased from 68 to 16% under the combination of S. boulardii. The results were consistent with the recent repots on the efficacy and safety of additional S. boulardii and probiotics in eradicating H. pylori (Cindoruk et al, 2007;Song et al, 2010).…”

Meta-analysis of the efficacy of probiotics inHelicobacter pylorieradication therapy

“…Deguchi et al [19] Culture, Histology, RUT UBT, HpSA 8 wk 5.20% Not reported Mirzaee et al [20] UBT UBT 4 wk 16.20% Non-Boer Canducci et al [21] UBT, Histology UBT, Histology, Endoscopy 6 wk 2.50% By de Boer et al Nista et al [22] UBT UBT 6 wk 5.70% By de Boer et al Sheu et al [23] Histology, RUT UBT, Histology, RUT 4 wk 1 6.90% Non-Boer 8 wk 2 Myllyluoma et al [24] Rapid whole blood test, UBT, EIA serology [25] Histology UBT 4 wk 8.90% Non-Boer Kim et al [26] RUT, Histology UBT 4-6 wk 3.00% Non-Boer Scaccianoce et al [27] Histology UBT 4-6 wk 3.00% Non-Boer Cindoruk et al [28] Histology of H. pylori [29,30] . For the past few years, the standard triple therapy, as recommended by the Maastricht 2-2000 Consensus Report, is regarded as the first-line treatment.…”

“…However, the Maastricht 4-2012 Consensus Report recommends sequential or concomitant regimens as the best first-line treatments in areas with high rates of clar- [17] (Korea) [18] (China) [19] (Japan) [20] (Iran) [21] (Italy) [24] (Finland) [25] (Turkey) [26] (Korea) [27] (Italy) [28] (Turkey) ithromycin resistance. Other treatment regimens include quadruple therapy and miscellaneous therapy.…”

“…Eighty-eight studies were excluded after more detailed assessments were made (21 studies were in animals or in vitro, 14 studies were in children, 13 studies did not use a standard triple therapy, 21 were unrelated studies, and 5 studies had no rigorous inclusion criteria), and the remaining 14 studies [15][16][17][18][19][20][21][22][23][24][25][26][27][28] were considered suitable for inclusion in the analysis. A flow diagram of the study selection process is shown in Figure 1.…”

Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders

“…S. boulardii induces morphologic changes in H. pylori cells consistent with cellular damage and was shown to cause reduction in H. pylori colonization in infected children by 12% [Gotteland et al 2005]. Of four RCTs testing S. boulardii in H. pylori infections, two were in children [Gotteland et al 2005;Hurduc et al 2009] and two in adults [Cindoruk et al 2007;Cremonini et al 2002]. Although there was no significant difference in H. pylori eradication between the S. boulardii and placebo groups, a significantly lower relative rate of AAD (16.1-25%) was observed.…”